Gilead Sciences (NASDAQ:GILD) Stock Acquired Rep. Marjorie Taylor Greene

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Gilead Sciences, Inc. NASDAQ: GILD. In a filing disclosed on June 18th, the Representative disclosed that they had bought between $1,001 and $15,000 in Gilead Sciences stock on June 6th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of lululemon athletica NASDAQ: LULU on 6/17/2025.
• Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 6/17/2025.
• Purchased $1,001 - $15,000 in shares of Tractor Supply NASDAQ: TSCO on 6/17/2025.
• Purchased $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 6/6/2025.
• Purchased $1,001 - $15,000 in shares of NextEra Energy NYSE: NEE on 6/6/2025.
• Purchased $1,001 - $15,000 in shares of Adobe NASDAQ: ADBE on 6/6/2025.
• Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 6/6/2025.
• Purchased $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 6/6/2025.
• Purchased $1,001 - $15,000 in shares of Netflix NASDAQ: NFLX on 6/6/2025.
• Purchased $1,001 - $15,000 in shares of UnitedHealth Group NYSE: UNH on 5/16/2025.

Gilead Sciences Trading Down 0.5%

GILD stock traded down $0.58 during mid-day trading on Friday, reaching $108.22. 6,627,889 shares of the stock traded hands, compared to its average volume of 7,673,118. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a one year low of $70.78 and a one year high of $119.96. The stock has a market capitalization of $134.62 billion, a PE ratio of 22.78, a PEG ratio of 0.70 and a beta of 0.29. The business has a 50-day moving average price of $108.81 and a two-hundred day moving average price of $105.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same period in the previous year, the firm earned ($1.32) earnings per share. The business's revenue was down .3% on a year-over-year basis. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.92%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the completion of the transaction, the chief executive officer owned 615,725 shares of the company's stock, valued at approximately $68,006,826.25. The trade was a 1.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the transaction, the chief financial officer directly owned 162,610 shares of the company's stock, valued at $18,054,588.30. The trade was a 1.51% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 72,000 shares of company stock worth $7,844,775. Corporate insiders own 0.27% of the company's stock.

Institutional Trading of Gilead Sciences

Hedge funds have recently made changes to their positions in the business. Bridgewater Associates LP increased its stake in Gilead Sciences by 122.7% in the fourth quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock valued at $42,577,000 after purchasing an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV boosted its position in shares of Gilead Sciences by 5.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after purchasing an additional 14,009 shares in the last quarter. Golden State Wealth Management LLC boosted its position in shares of Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after purchasing an additional 109 shares in the last quarter. Ontario Teachers Pension Plan Board boosted its position in shares of Gilead Sciences by 54.6% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock worth $3,422,000 after purchasing an additional 13,086 shares in the last quarter. Finally, Mufg Securities Americas Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter worth $1,699,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent analyst reports. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Oppenheimer lowered their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Morgan Stanley upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Finally, Cantor Fitzgerald began coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price for the company. Nine investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $111.38.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.